December 8, 2025Blood

High remission rates with FLAG-ida-venetoclax in acute myeloid leukemia: “Less is More” on days of venetoclax in the intensive regimen

View Full Paper

Ask AI

Bookmark

Overall response rates were 90% in frontline settings and 86% in the second induction cohort with FLAG-Ida-Ven.
A notable finding is the trend of prolonged neutropenia associated with venetoclax duration, underscoring monitoring needs.
Patients experienced high rates of febrile neutropenia, complicating recovery, especially in relapsed/refractory cases.
This regimen demonstrates effective responses even among patients with acute myeloid leukemia classified as high-risk.

Discussion

No takes yet. Share an insight, caveat, or question.

Real-world analysis shows FLAG-Ida-Ven achieves high remission rates in acute myeloid leukemia, indicating a need for optimal venetoclax duration.

Fedorov et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Real-world analysis shows FLAG-Ida-Ven achieves high remission rates in acute myeloid leukemia, indicating a need for optimal venetoclax duration.